LifeStance Health Group (NASDAQ:LFST) Director Sells $11,975.04 in Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 1,701 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.04, for a total transaction of $11,975.04. Following the completion of the transaction, the director owned 1,318,133 shares in the company, valued at $9,279,656.32. This trade represents a 0.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Robert Bessler also recently made the following trade(s):

• On Friday, December 19th, Robert Bessler sold 119,942 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.04, for a total value of $844,391.68.
• On Thursday, December 18th, Robert Bessler sold 6,442 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total value of $45,094.00.
• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total value of $86,597.00.
• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total transaction of $558,206.30.

LifeStance Health Group Stock Up 0.1%

Shares of LifeStance Health Group stock traded up $0.01 during trading on Tuesday, reaching $7.06. 1,276,911 shares of the company traded hands, compared to its average volume of 2,381,689. The firm has a market capitalization of $2.75 billion, a PE ratio of -235.33 and a beta of 1.13. LifeStance Health Group, Inc. has a 1-year low of $3.74 and a 1-year high of $8.30. The company has a 50 day moving average price of $6.07 and a 200-day moving average price of $5.38. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.03. The firm had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business’s revenue was up 16.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.02) earnings per share. As a group, equities research analysts expect that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Tudor Investment Corp ET AL purchased a new stake in LifeStance Health Group during the third quarter valued at about $1,040,000. CIBC Bancorp USA Inc. bought a new position in LifeStance Health Group in the 3rd quarter worth approximately $78,000. Jacobs Levy Equity Management Inc. raised its holdings in LifeStance Health Group by 1.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,147,690 shares of the company’s stock valued at $11,812,000 after acquiring an additional 38,528 shares during the period. Dark Forest Capital Management LP bought a new stake in LifeStance Health Group during the 3rd quarter valued at $140,000. Finally, PharVision Advisers LLC purchased a new stake in shares of LifeStance Health Group during the third quarter worth $84,000. Institutional investors own 85.50% of the company’s stock.

Wall Street Analyst Weigh In

LFST has been the topic of a number of recent research reports. BMO Capital Markets began coverage on LifeStance Health Group in a report on Thursday, November 13th. They issued an “outperform” rating and a $8.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday. UBS Group boosted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Wall Street Zen cut shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, BTIG Research lifted their price target on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $8.83.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.